Dalbavancin (BI-387) for the treatment of complicated skin and skin structure infection.

Article Details

Citation

Copy to clipboard

Leuthner KD, Yuen A, Mao Y, Rahbar A

Dalbavancin (BI-387) for the treatment of complicated skin and skin structure infection.

Expert Rev Anti Infect Ther. 2015 Feb;13(2):149-59. doi: 10.1586/14787210.2015.995633.

PubMed ID

25578881 [ View in PubMed

]

Abstract

In the era of increasing antibiotic resistance, development of new agents that could provide therapeutic options for difficult to treat pathogens is vital. Dalbavancin is a new lipoglycopeptide recently approved by the US FDA for the treatment of acute bacterial skin and skin structure infections. A derivative of the older glycopeptide class, chemical structure alterations resulted in a molecule with a similar mechanism of action, however, with a comparatively increased activity as reflected by organism MICs. These modifications also resulted in an antibiotic with distinctive properties that allow for once-weekly dosing in the treatment of Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus and drug resistant Streptococcus spp. As the first of these long acting compounds, understanding the pharmacokinetic and pharmacodynamic properties of agents like dalbavancin is essential for determining a place in therapy.

DrugBank Data that Cites this Article

Drugs

Dalbavancin

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Dalbavancin	D-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycan	Group	Gram-positive Bacteria	Yes	Binder	Details